Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Sight Sciences (SGHT) Cash from Financing Activities (2020 - 2025)

Sight Sciences has reported Cash from Financing Activities over the past 6 years, most recently at $1.3 million for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $1.3 million for Q4 2025, down 76.53% from a year ago — trailing twelve months through Dec 2025 was $1.8 million (down 63.92% YoY), and the annual figure for FY2025 was $1.8 million, down 63.92%.
  • Cash from Financing Activities for Q4 2025 was $1.3 million at Sight Sciences, up from $25000.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for SGHT hit a ceiling of $252.7 million in Q3 2021 and a floor of -$942000.0 in Q1 2024.
  • Median Cash from Financing Activities over the past 5 years was $138000.0 (2022), compared with a mean of $13.1 million.
  • Biggest five-year swings in Cash from Financing Activities: soared 148748.24% in 2021 and later tumbled 503.85% in 2024.
  • Sight Sciences' Cash from Financing Activities stood at $91000.0 in 2021, then surged by 792.31% to $812000.0 in 2022, then crashed by 53.69% to $376000.0 in 2023, then skyrocketed by 1333.24% to $5.4 million in 2024, then tumbled by 76.53% to $1.3 million in 2025.
  • The last three reported values for Cash from Financing Activities were $1.3 million (Q4 2025), $25000.0 (Q3 2025), and $485000.0 (Q2 2025) per Business Quant data.